TG THERAPEUTICS, INC. Long-Term Debt, Maturity, Year Two and Three
TG THERAPEUTICS, INC. (TGTX) had Long-Term Debt, Maturity, Year Two and Three of $100.40 million as of 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturingInYearsTwoAndThree · last filed 2024-02-29
- 2023-12-31: Long-Term Debt, Maturity, Year Two and Three $100.40M.
| Period end | Long-Term Debt, Maturity, Year Two and Three |
|---|---|
| 2023-12-31 | $100.40M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |